This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups. You can read the earlier stories in the series here.
Early-stage biotech companies can make some big promises to their investors — lofty claims that they’re creating the first drug to treat a disease or first to use a new kind of biology or chemistry. And in return for those promises, investors hand over millions of dollars.
But early-stage companies are private. For outsiders, sporadic press releases contain clues about where a company’s headed — but asking the company’s leadership and staff is the only real way to find out exactly what’s going on.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect